EGFR and non-small cell lung carcinoma: Because the combination of chemotherapy and EGFR TKIs showed cytotoxic synergism against wild-type EGFR NSCLC cell lines in a preclinical study [12, 13] and this combination was suggested as a new treatment option for patients with unknown EGFR status in a previous clinical study [21], we hypothesized that the intercalated strategy could be effective in patients with wild-type or unknown EGFR status.